Back
EHRA Premium Access

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

Session: Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death
Topic: Prevention
Speaker: Doctor S. Reif (Munich, DE)
Sponsored by ZOLL
Event: EHRA 2019

Congress Presentation

About the speaker

Doctor Sebastian Reif

Munich Clinic Bogenhausen, Munich (Germany)
2 presentations
0 follower

4 more presentations in this session

Introduction - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor G. Botto (Garbagnate Milanese, IT)

Access
Slides
Video
Thumbnail

Strategies for screening and identifying which patients to protect with the WCD.

Speaker: Professor J. Ehrlich (Wiesbaden, DE)

Access
Slides
Video
Thumbnail

The impact of the WCD for patients who choose to wear it.

Speaker: Professor D. Scherr (Graz, AT)

Access
Slides
Video
Thumbnail

Panel discussion and summary - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor O. Piot (Saint Denis, FR)

Access
Slides
Video
Thumbnail

Access the full session

Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

Speakers: Doctor S. Reif, Doctor G. Botto, Professor J. Ehrlich, Professor D. Scherr, Doctor O. Piot
Access
Thumbnail

About the event

Image

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb